Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line CLL trial comparing chemoimmunotherapy with venetoclax-based combinations
NL-OMON54622Phase 3Completed
- Sponsor
- University of Cologne
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, obinutuzumab, ibrutinib, rituximab, fludarabine and 2 more in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by University of Cologne. Primary endpoints: Peripheral blood MRD negativity at month 15 and Progression-free survival. Started May 2017; status: completed.
02
Drugs
venetoclaxobinutuzumabibrutinibrituximabfludarabine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON54622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54622.